New antibody combo aims to tackle Hard-to-Treat multiple myeloma

NCT ID NCT02332850

Completed Disease control Sponsor: Thomas Martin, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body tolerates the combination. Participants receive the drugs intravenously, and the study tracks side effects and initial signs of tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Isatuximab (a monoclonal antibody) combined with carfilzomib and dexamethasone
What this could lead to: If successful, this could lead to a more effective treatment option for people with multiple myeloma that has returned or not responded to prior therapies.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it is not yet known if the combination works better than existing treatments. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2C1, Canada
Sarah Cannon Cancer Center

Nashville, Tennessee, 37203, United States
University of California, San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.